These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 24530403

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.
    Vaccine; 2006 May 01; 24(18):3953-63. PubMed ID: 16530302
    [Abstract] [Full Text] [Related]

  • 46. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
    Zeng M, Xu Q, Pichichero ME.
    Vaccine; 2007 May 04; 25(18):3588-94. PubMed ID: 17293013
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK, Gross T, Larabee J, Pate L, Cuthbertson H, Charlton S, Hallis B, Engler RJM, Collins LC, Spooner CE, Chen H, Ballard J, James JA, Farris AD.
    Clin Vaccine Immunol; 2017 Nov 04; 24(11):. PubMed ID: 28877928
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.
    Klinman DM, Klaschik S, Tomaru K, Shirota H, Tross D, Ikeuchi H.
    Vaccine; 2010 Feb 23; 28(8):1919-23. PubMed ID: 20188247
    [Abstract] [Full Text] [Related]

  • 51. Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.
    Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R.
    Clin Vaccine Immunol; 2012 Feb 23; 19(2):140-5. PubMed ID: 22190398
    [Abstract] [Full Text] [Related]

  • 52. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.
    Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM.
    Vaccine; 2002 Jan 31; 20(9-10):1412-20. PubMed ID: 11818160
    [Abstract] [Full Text] [Related]

  • 53. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK, Garman L, Cuthbertson H, Charlton S, Hallis B, Engler RJM, Choudhari S, Picking WD, James JA, Farris AD.
    Vaccine; 2017 Jun 08; 35(26):3416-3422. PubMed ID: 28504191
    [Abstract] [Full Text] [Related]

  • 54. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.
    Feinen B, Petrovsky N, Verma A, Merkel TJ.
    Clin Vaccine Immunol; 2014 Apr 08; 21(4):580-6. PubMed ID: 24554695
    [Abstract] [Full Text] [Related]

  • 55. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS, Lee JH, Hung CF, Wu TC, Kim TW.
    Infect Immun; 2008 May 08; 76(5):1952-9. PubMed ID: 18285494
    [Abstract] [Full Text] [Related]

  • 56. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.
    Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.
    Hum Vaccin; 2007 May 08; 3(5):205-11. PubMed ID: 17881903
    [Abstract] [Full Text] [Related]

  • 57. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S, Little S, Friedlander A, Fritz D, Fellows P.
    Microbiology (Reading); 2001 Jun 08; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [Abstract] [Full Text] [Related]

  • 58. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
    Lininger LA, Cullum ME, Lyles MB, Bienek DR.
    Vaccine; 2007 Feb 19; 25(9):1619-25. PubMed ID: 17150286
    [Abstract] [Full Text] [Related]

  • 59. CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits.
    Zhao F, Liu S, Zhang X, Yu J, Zeng T, Gu W, Cao X, Chen X, Wu Y.
    Hum Vaccin Immunother; 2013 Apr 19; 9(4):753-60. PubMed ID: 23563515
    [Abstract] [Full Text] [Related]

  • 60. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.
    Yu YZ, Ma Y, Xu WH, Wang S, Sun ZW.
    Med Microbiol Immunol; 2015 Aug 19; 204(4):481-91. PubMed ID: 25265876
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.